Company

Brise Pharmaceuticals Announces Its 2024 License Deal Value With AbbVie Could Reach Up To $775M For Two Of Brise's Preclinical Migraine Programs

Nov 2, 2026 · 09:06 AM ET· updated 2h ago

Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is

Why It Matters

Brise and AbbVie made a deal worth up to $775 million. This shows a big company believes in Brise's migraine medicine ideas enough to pay for them.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ABBV287.40

-7.49 (-2.54%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.